Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
260 GBX | +3.17% | +1.96% | +11.59% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Apr. 11 | Mears Group ups dividend on higher profit | AN |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With a 2024 P/E ratio at 24.71 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.59% | 660M | B- | ||
-0.81% | 121B | A- | ||
+5.52% | 97.29B | C+ | ||
+13.89% | 68.9B | - | B+ | |
+21.34% | 64.34B | C | ||
+13.26% | 44.5B | C+ | ||
+14.02% | 43.12B | A- | ||
+22.97% | 36.25B | A- | ||
+8.77% | 26.07B | B | ||
-0.40% | 23.5B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XPS Stock
- Ratings XPS Pensions Group plc